surpass 5 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Latest Data From SURPASS Trials

Description

Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis

Call 999 or go to your nearest emergency department immediately if: You experience sudden, severe dizziness with loss of balance, difficulty speaking, facial drooping, or weakness in the limbs these may be signs of a stroke and require immediate assessment You faint or lose consciousness You experience chest pain or severe shortness of breath alongside dizziness For those participating in a clinical trial, all adverse events including dizziness should be reported to the trial team in accordance with the study protocol, regardless of perceived severity

Your healthcare team should also review all concurrent medications for potential interactions and assess your individual risk factors before approving the switch